et al. et al. et al. et al. et al. et al. et al. et al. et al. et al.
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
REVIEW

A brief history of economic evaluation for human papillomavirus vaccination policy

Philippe Beutels A B D and Mark Jit C

A Present address: Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp 2610, Belgium.

B School of Public Health, University of Sydney, Sydney, NSW 2006, Australia.

C Modelling and Economics Unit, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK.

D Corresponding author. Email: philippe.beutels@ua.ac.be

Sexual Health 7(3) 352-358 https://doi.org/10.1071/SH10018
Submitted: 16 February 2010  Accepted: 28 May 2010   Published: 19 August 2010

Abstract

Background: This commentary discusses key issues for health economic evaluation and modelling, applied to human papillomavirus (HPV) vaccine programs. Methods: We outline some of the specific features of HPV disease and vaccination, and associated policy questions in light of a literature search for economic evaluations on HPV vaccination. Results: We observe that some policy questions could not be reliably addressed by many of the 43 published economic evaluations we found. Despite this, policy making on universal HPV vaccination followed shortly after vaccine licensure in many developed countries, so the role economic evaluation played in informing these decisions (pre-dating 2008) seems to have been fairly limited. For more recent decisions, however, economic evaluation is likely to have been used more widely and more intensively. Conclusions: We expect future cost-effectiveness analyses to be more instrumental in policy making regarding vaccines covering more HPV types, therapeutic HPV vaccines, and novel diagnostic tests for biomarkers of HPV infection and disease integrated with cervical screening programs.

Additional keywords: HPV, modelling, vaccine programs.


References


[1] zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology 2009; 384 260–5.
CrossRef | PubMed |

[2] Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118 3030–44.
CrossRef | PubMed |

[3] Gustafsson L,  Ponten J,  Zack M,  Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8 755–63.
CrossRef | PubMed |

[4] Munoz N,  Bosch FX,  de Sanjose S,  Herrero R,  Castellsague X,  Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 518–27.
CrossRef | PubMed |

[5] von Krogh G,  Lacey CJ,  Gross G,  Barrasso R,  Schneider A. European guideline for the management of anogenital warts. Int J STD AIDS 2001; 12 40–7.
CrossRef | PubMed |

[6] Bouvard V,  Baan R,  Straif K,  Grosse Y,  Secretan B,  El Ghissassi F, et al. A review of human carcinogens – Part B: biological agents. Lancet Oncol 2009; 10 321–2.
CrossRef | PubMed |

[7] Poolman EM,  Elbasha EH,  Galvani AP. Vaccination and the evolutionary ecology of human papillomavirus. Vaccine 2008; 26(Suppl 3): C25–30.
CrossRef | PubMed |

[8] Newmann SJ,  Garner EO. Social inequities along the cervical cancer continuum: a structured review. Cancer Causes Control 2005; 16 63–70.
CrossRef | PubMed |

[9] Goldstein ST,  Cassidy WM,  Hodgson W,  Mahoney FJ. Factors associated with student participation in a school-based hepatitis B immunization program. J Sch Health 2001; 71 184–7.
CrossRef | PubMed |

[10] Wilson TR,  Fishbein DB,  Ellis PA,  Edlavitch SA. The impact of a school entry law on adolescent immunization rates. J Adolesc Health 2005; 37 511–6.
CrossRef | PubMed |

[11] Vandermeulen C,  Roelants M,  Theeten H,  Depoorter AM,  Van Damme P,  Hoppenbrouwers K. Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants. Pediatrics 2008; 121 e428–34.
CrossRef | PubMed |

[12] Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007; 111 145–53.
CrossRef | PubMed |

[13] Cuzick J,  Arbyn M,  Sankaranarayanan R,  Tsu V,  Ronco G,  Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26(Suppl 10): K29–41.
CrossRef | PubMed |

[14] Drummond M , O’Brien B , Stoddart G , Torrance G . Methods for the economic evaluation of health care programmes (2nd edn). New York: Oxford University Press; 1997.

[15] Beutels P,  Scuffham PA,  MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008; 8 727–33.
CrossRef | PubMed |

[16] Jit M,  Choi YH,  Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337 a769.
CrossRef | PubMed |

[17] Kim SY,  Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26 191–215.
CrossRef | PubMed |

[18] Walker DG,  Hutubessy R,  Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010; 28 2356–9.
CrossRef | PubMed |

[19] Kim JJ,  Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339 b3884.
CrossRef | PubMed |

[20] Kim JJ,  Kobus KE,  Diaz M,  O’Shea M,  Van Minh H,  Goldie SJ. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008; 26 4015–24.
CrossRef | PubMed |

[21] Kulasingam S,  Connelly L,  Conway E,  Flocking JS,  Myers E,  Regan DG, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007; 4 165–75.
CrossRef | PubMed |

[22] Dervaux B , Lenne X , Lévy-Bruhl D , Kudjawu Y . Modélisation médico-économique de l’impact de l’organisation du dépistage du cancer du col utérin et de l’introduction de la vaccination contre les HPV dans le calendrier vaccinal – Mars 2007. Paris: Saint Maurice; 2008.

[23] Marra F,  Cloutier K,  Oteng B,  Marra C,  Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27 127–47.
CrossRef | PubMed |

[24] Brisson M,  Van de Velde N,  Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomi 2009; 12 343–51.
CrossRef |

[25] Kulasingam SL,  Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290 781–9.
CrossRef | PubMed |

[26] Sanders GD,  Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9 37–48.
PubMed |

[27] Goldie SJ,  Kohli M,  Grima D,  Weinstein MC,  Wright TC,  Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96 604–15.
CrossRef | PubMed |

[28] Taira AV,  Neukermans CP,  Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10 1915–23.
PubMed |

[29] Dasbach EJ,  Elbasha EH,  Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28 88–100.
CrossRef | PubMed |

[30] Brisson M,  Van de Velde N,  De Wals P,  Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25 5399–408.
CrossRef | PubMed |

[31] Ginsberg GM,  Fisher M,  Ben-Shahar I,  Bornstein J. Cost-utility analysis of vaccination against HPV in Israel. Vaccine 2007; 25 6677–91.
CrossRef | PubMed |

[32] Goldie SJ,  Kim JJ,  Kobus K,  Goldhaber-Fiebert JD,  Salomon J,  O’Shea MKH, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007; 25 6257–70.
CrossRef | PubMed |

[33] Insinga RP,  Dasbach EJ,  Elbasha EH,  Puig A,  Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007; 26 128–39.
CrossRef | PubMed |

[34] Kim JJ,  Andres-Beck B,  Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007; 97 1322–8.
CrossRef | PubMed |

[35] Bergeron C,  Largeron N,  McAllister R,  Mathevet P,  Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess 2008; 24 10–9.


[36] Chesson HW,  Ekwueme DU,  Saraiya M,  Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14 244–51.
CrossRef | PubMed |

[37] Chesson HW,  Forhan SE,  Gottlieb SL,  Markowitz LE. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 2008; 26 4513–8.
CrossRef | PubMed |

[38] Dasbach EJ,  Insinga RP,  Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008; 115 947–56.
CrossRef | PubMed |

[39] Dasbach EJ,  Insinga RP,  Yang YC,  Pwu RF,  Lac C,  Elbasha EH. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac J Cancer Prev 2008; 9 459–66.
PubMed |

[40] Diaz M,  Kim JJ,  Albero G,  de Sanjose S,  Clifford G,  Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008; 99 230–8.
CrossRef | PubMed |

[41] Goldhaber-Fiebert JD,  Stout NK,  Salomon JA,  Kuntz KM,  Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008; 100 308–20.
CrossRef | PubMed |

[42] Goldie SJ,  O’Shea M,  Campos NG,  Diaz M,  Sweet S,  Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008; 26 4080–93.
CrossRef | PubMed |

[43] Insinga RP,  Dasbach EJ,  Allen SE,  Carides G,  Myers ER. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE study economic evaluation. Value Health 2008; 11 1022–32.
CrossRef | PubMed |

[44] Kim JJ,  Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359 821–32.
CrossRef | PubMed |

[45] Kulasingam SL,  Benard S,  Barnabas RV,  Largeron N,  Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008; 6 4.
CrossRef | PubMed |

[46] Llamazares M,  Smith RJ. Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination? BMC Public Health 2008; 8 114.
CrossRef | PubMed |

[47] Prasad SR,  Hill R. Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky. J Ky Med Assoc 2008; 106 271–6.
CrossRef | PubMed |

[48] Szucs TD,  Largeron N,  Dedes KJ,  Rafia R,  Benard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008; 24 1473–83.
CrossRef | PubMed |

[49] Usher C,  Tilson L,  Olsen J,  Jepsen M,  Walsh C,  Barry M. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 2008; 26 5654–61.
CrossRef | PubMed |

[50] Annemans L,  Remy V,  Oyee J,  Largeron N. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27 231–45.
CrossRef | PubMed |

[51] de Kok I,  van Ballegooijen M,  Habbema JDF. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009; 101 1083–92.
CrossRef | PubMed |

[52] Dee A,  Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2009; Nov 11.


[53] Kim JJ,  Ortendahl J,  Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009; 151 538–45.
PubMed |

[54] Mennini FS,  Rossi PG,  Palazzo F,  Largeron N. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009; 112 370–6.
CrossRef | PubMed |

[55] Oddsson K,  Johannsson J,  Asgeirsdottir TL,  Gudnason T. Cost-effectiveness of human papilloma virus vaccination in Iceland. Acta Obstet Gynecol Scand 2009; 88 1411–6.
CrossRef | PubMed |

[56] Reynales-Shigematsu LM,  Rodrigues ER,  Lazcano-Ponce E. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009; 40 503–13.
CrossRef | PubMed |

[57] Rogoza RM,  Westra TA,  Ferko N,  Tamminga JJ,  Drummond MF,  Daemen T, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009; 27 4776–83.
CrossRef | PubMed |

[58] Sinanovic E,  Moodley J,  Barone MA,  Mall S,  Cleary S,  Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 2009; 27 6196–202.
CrossRef | PubMed |

[59] Thiry N,  De Laet C,  Hulstaert F,  Neyt M,  Huybrechts M,  Cleemput I. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009; 25 161–70.
CrossRef | PubMed |

[60] Wong G,  Howard K,  Webster A,  Chapman JR,  Craig JC. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation 2009; 87 1078–91.
CrossRef | PubMed |

[61] Zechmeister I,  de Blasio BF,  Garnett G,  Neilson AR,  Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009; 27 5133–41.
CrossRef | PubMed |

[62] Liu PH,  Hu FC,  Lee PI,  Chow SN,  Huang CW,  Wang JD. Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. BMC Health Serv Res 2010; 10 11.
CrossRef | PubMed |

[63] Dasbach EJ,  Nagy L,  Brandtmuller A,  Elbasha EH. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ 2010; 13 110–8.
CrossRef | PubMed |

[64] Dasbach EJ,  Elbasha EH,  Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28 88–100.
CrossRef | PubMed |

[65] Insinga RP,  Dasbach EJ,  Elbasha EH. Structural differences among cost-effectiveness models of human papillomavirus vaccines. Expert Rev Vaccines 2008; 7 895–913.
CrossRef | PubMed |

[66] Jeurissen S,  Makar A. Epidemiological and economic impact of human papillomavirus vaccines. Int J Gynecol Cancer 2009; 19 761–71.
PubMed |

[67] Newall AT,  Beutels P,  Wood JG,  Edmunds WJ,  MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007; 7 289–96.
CrossRef | PubMed |

[68] Puig-Junoy J,  Lopez-Valcarcel BG. Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained. Prev Med 2009; 48 444–8.
CrossRef | PubMed |

[69] Techakehakij W,  Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 2008; 26 6258–65.
CrossRef | PubMed |

[70] Van de Velde N,  Brisson M,  Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007; 165 762–75.
CrossRef | PubMed |

[71] Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics 2008; 26 589–602.
CrossRef | PubMed |

[72] Bos JM,  Beutels P,  Annemans L,  Postma MJ. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics 2004; 22 1171–9.
CrossRef | PubMed |

[73] Frederick S,  Loewenstein G,  O’Donoghue T. Time discounting and time preference: a critical review. J Econ Lit 2002; 40 351–401.
CrossRef |

[74] Australian Government. PBAC Outcomes – 1st time decisions not to recommend. Canberra: Department of Health and Ageing; 2006. Available online at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-nov06-1st_time [verified May 2010].

[75] Levy-Bruhl D,  Bousquet V,  King LA,  O’Flanagan D,  Bacci S,  Lopalco PL, et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Eur J Cancer 2009; 45 2709–13.
CrossRef | PubMed |

[76] Koulova A,  Tsui J,  Irwin K,  Van Damme P,  Biellik R,  Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008. Vaccine 2008; 26 6529–41.
CrossRef | PubMed |

[77] Elbasha EH,  Dasbach EJ,  Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13 28–41.
CrossRef | PubMed |

[78] Hall A. The United Kingdom joint committee on vaccination and immunisation. Vaccine 2010; 28(Suppl 1): A54–7.
CrossRef |

[79] Advisory Committee on Immunization Practices in the United States. Considerations for HPV vaccines in males. Atlanta: Centers for Disease Control and Prevention; 2009. Available online at: http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct09/02-9-hpv.pdf [verified May 2010].

[80] Clement FM,  Harris A,  Li JJ,  Yong K,  Lee KM,  Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009; 302 1437–43.
CrossRef | PubMed |

[81] Roughead EE,  Gilbert AL,  Vitry AI. The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy. Health Policy 2008; 88 250–7.
CrossRef | PubMed |

[82] Haas M,  Ashton T,  Blum K,  Christiansen T,  Conis E,  Crivelli L, et al. Drugs, sex, money and power: an HPV vaccine case study. Health Policy 2009; 92 288–95.
CrossRef | PubMed |

[83] Brinsmead R,  Hill S,  Walker D. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 2004; 23 32–7.
CrossRef | PubMed |

[84] Welte R,  Trotter CL,  Edmunds WJ,  Postma MJ,  Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics 2005; 23 855–74.
CrossRef | PubMed |

[85] Zanetti AR,  Van Damme P,  Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26 6266–73.
CrossRef | PubMed |



Rent Article (via Deepdyve) Export Citation Cited By (17)